Replies to post #214458 on Biotech Values

[DewDiligence]

ENTA—Mavyret US scripts—week ending 10/20/17 (according to IMS)….

TRx: 739, +19.6% vs prior week
NRx: 418, +16.8% vs prior week

We are now 12 weeks into the US launch.

(As previously noted, Mavyret’s absolute script numbers reported by IMS are low because IMS misses much of the public sector of the HCV market that ABBV is targeting.)